Literature DB >> 19075161

Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab.

Susan Bard, Alexandra Paravisini, José Antonio Avilés-Izquierdo, Eduardo Fernandez-Cruz, Silvia Sánchez-Ramón.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075161     DOI: 10.1001/archdermatol.2008.510

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  10 in total

Review 1.  Hyperimmunoglobulin E syndromes in pediatrics.

Authors:  Qian Zhang; Helen C Su
Journal:  Curr Opin Pediatr       Date:  2011-12       Impact factor: 2.856

Review 2.  Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.

Authors:  Tejas P Joshi; Hannah Y Wang; Prazwal Athukuri; Sarah Bohac; Morgan A Farr; Darien Hinson; Justin A Kahla; Nasim Khalfe; Dylan B McBee; Rachel Stroh; Nicole Walters; Vicky Ren
Journal:  Am J Clin Dermatol       Date:  2022-05-23       Impact factor: 6.233

3.  Allergic manifestations of inborn errors of immunity and their impact on the diagnosis: A worldwide study.

Authors:  Zeinab A El-Sayed; Dalia H El-Ghoneimy; José A Ortega-Martell; Nesrine Radwan; Juan C Aldave; Waleed Al-Herz; Maryam A Al-Nesf; Antonio Condino-Neto; Theresa Cole; Brian Eley; Nahla H H Erwa; Sara Espinosa-Padilla; Emilia Faria; Nelson A Rosario Filho; Ramsay Fuleihan; Nermeen Galal; Elizabeth Garabedian; Mary Hintermeyer; Kohsuke Imai; Carla Irani; Ebtihal Kamal; Nadia Kechout; Adam Klocperk; Michael Levin; Tomas Milota; Monia Ouederni; Roberto Paganelli; Claudio Pignata; Farah N Qamar; Isabella Quinti; Sonia Qureshi; Nita Radhakrishnan; Nima Rezaei; John Routes; Surjit Singh; Sangeetha Siniah; Intisar Abdel-Hakam Taha; Luciana K Tanno; Ben Van Dort; Alla Volokha; Kathleen Sullivan
Journal:  World Allergy Organ J       Date:  2022-06-17       Impact factor: 5.516

4.  Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review.

Authors:  Jun Lan; Yi Zhang; Min Song; Shan Cai; Hong Luo; Ruoyun OuYang; Pan Yang; Xiaoliu Shi; Yingjiao Long; Yan Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-04

Review 5.  An overview of the effects of anti-IgE therapies.

Authors:  Arzu Didem Yalcin
Journal:  Med Sci Monit       Date:  2014-09-22

6.  Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome.

Authors:  Cesar Daniel Alonso-Bello; María Del Carmen Jiménez-Martínez; María Eugenia Vargas-Camaño; Sagrario Hierro-Orozco; Mario Alberto Ynga-Durand; Laura Berrón-Ruiz; Julio César Alcántara-Montiel; Leopoldo Santos-Argumedo; Diana Andrea Herrera-Sánchez; Fernando Lozano-Patiño; María Isabel Castrejón-Vázquez
Journal:  Case Reports Immunol       Date:  2019-07-04

Review 7.  Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.

Authors:  Andreas Wollenberg; Simon Francis Thomsen; Jean-Philippe Lacour; Xavier Jaumont; Slawomir Lazarewicz
Journal:  World Allergy Organ J       Date:  2021-03-19       Impact factor: 4.084

8.  Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.

Authors:  Simona Barni; Mattia Giovannini; Giulia Liccioli; Lucrezia Sarti; Anna Gissi; Paolo Lionetti; Francesca Mori
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

9.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

10.  Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency.

Authors:  Pasquale Comberiati; Giorgio Costagliola; Niccolò Carli; Annalisa Legitimo; Sofia D'Elios; Rita Consolini; Diego G Peroni
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.